Saturday, May 31, 2025

Latest

FDA Grants PharmaTher Pre-IND Meeting For Treatment Of Parkinson’s With Ketamine

PharmaTher Inc (CSE: PHRM) this morning announced that the US Food and Drug Administration has granted the company a pre-investigational new drug meeting. The meeting, which was filed for earlier this week, is in connection with the clinical development of ketamine for use against Parkinson’s Disease, as well as a currently proposed phase 2 clinical study for using the psychedelic compound in the treatment of levodopa-induced dyskinesia associated with Parkinson’s.

The current timeline for the written response meeting indicates that the meeting should be conducted by the end of January 2021. Furthermore, PharmaTher has stated that it has substantially completed its application for an investigational new drug, and upon receiving responses from the FDA, intends to file and begin a phase 2 study on the use of ketamine for the treatment of levodopa induced dyskinesia, or the loss of motor controls, within the first quarter of 2021.

The meeting to be conducted with the FDA is anticipated to provide the required information to submit this application, and enable the company to continue along the FDA regulatory pathway.

“We are pleased that our initiatives focused on the FDA regulatory pathway for ketamine continues its momentum and the IND builds a foundation where we can develop an FDA approved ketamine for not only Parkinson’s disease, but also for the millions of people worldwide affected by movement disorders, depression and pain.”

Fabio Chianelli, CEO of PharmaTher

PharmaTher last traded at $0.27 on the CSE.


FULL DISCLOSURE: Pharmather is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Pharmather on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Leave a Reply

Video Articles

How To Profit From $3300 Gold? An Inside Look At A Massive 300,000 Oz Project | Martino De Ciccio

We’re At The Start of a Great Silver Boom | Ross McElroy & Andy Bowering – Apollo Silver Corp

Equinox Gold Q1 Earnings: When Everything Goes Wrong

Recommended

ESGold Begins Concentration Tests Ahead Of First Production

Sterling Metals Hits 0.21% Copper Over 482.8 Metres In First Drilling At Soo Copper project

Related News

FDA Gives Elon Musk’s Neuralink Approval To Test On Human Brains While Animal Harm Reports Still Loom

Elon Musk’s brain-implant firm Neuralink announced that the Food and Drug Administration (FDA) has approved...

Friday, May 26, 2023, 08:14:34 AM

JUUL Slapped with FDA Warning Letter for Health Claims

JUUL Labs, an e-cigarette products company that is 35% owned by Altria (NYSE: MO) and...

Monday, September 9, 2019, 12:01:14 PM

Pharmather: Combining Artificial Intelligence With Psychedelics For Novel Drug Discovery

Newscope Capital, whom is currently doing business as Pharmather (CSE: PHRM) is the latest firm...

Monday, October 12, 2020, 03:47:00 PM

PharmaTher Acquires Exclusive Rights To Patented Ketamine Formulation

PharmaTher Inc (CSE: PHRM) has entered into an exclusive worldwide license agreement for the development...

Tuesday, January 19, 2021, 09:24:20 AM

Pharmather Applies For Orphan Drug Status For Ketamine In Use Against Parkinson’s Disease

Pharmather Inc (CSE: PHRM) has filed for orphan drug designation with the US Food and...

Tuesday, October 20, 2020, 09:30:33 AM